ZYBERNO
Stock Report
Updated Aug 30, 2026

BENITEC BIOPHARMA INC. (BNTC)

Healthcare • NASDAQ

$12.47

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
20.0/100
POOR BUSINESS
BENITEC BIOPHARMA INC. (BNTC) scores 20/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-29.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,560.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BENITEC BIOPHARMA INC. (BNTC) stock report — Zyberno Score 20/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, BNTC generated -$15.91M in Owner Earnings. Capital was deployed as follows: $13.00K invested in capital expenditures. Reinvestment rate: -0.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:12.47
Market Cap:$615.85M

Valuation Multiples (2)

P/B Ratio:3.36x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$431.96M

Price Action & Momentum (3)

Momentum Percentile:59 / 100
% of 52-Week High:74.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-28.7%
Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):4.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$7.54
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-125.5%
Latest Earnings Filed:2026-05-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-45.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:56.82x
Quick Ratio:56.82x
Cash Ratio:56.43x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:182,743,000.00
Cash And Cash Equivalents:184,761,000.00
Long Term Debt:$394.00K
Net Debt:-$183.89M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $0.00
Linear Growth: -45.7%
📊 Click to view full BNTC Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$46.60M

Bottom Line Performance (3)

-$41.54M
Income Before Tax:-$37.18M
Ebitda Ttm:-46,542,000.00

Operating Expenses (5)

Operating Expenses:46,596,000.00
R And D Expense:18,369,000.00
Sga Expense:28,227,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$187.00M
Current Assets:$186.02M
Ppe Net:1,416,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,668,000.00
Current Liabilities:3,274,000.00
Long Term Debt:$394.00K
Short Term Debt:$482.00K

Equity & Capital (3)

Equity:$183.33M
Retained Earnings:-$260.91M
Common Stock:160,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:0.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:7,592,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.40M-$19.42M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:13,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:18,800,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:54,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.93
-$0.93
Earnings Per Share Ttm:-$0.84

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.39

Book Value & Capital (2)

Book Value Per Share:$3.71
Cash Per Share:3.74

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$15.91M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):4.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-45.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):91.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:BNTC
Company Name:BENITEC BIOPHARMA INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:49.39M
Shares Outstanding Basic:49.39M
Shares Outstanding Diluted:49.39M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 20:25:59 UTC
Data Timestamp:2026-08-17T22:00:35.158496
Scroll to Top